Assertio (ASRT) Insider Stark David Matthew Sells 5,415 Shares

David Matthew Stark sold 5,415 shares of Assertio Holdings Inc (ASRT) on June 16, 2026. This transaction was part of a larger wave of selling by the company's top leadership on that same Tuesday. While the specific dollar value for Stark's trade wasn't disclosed in the filing, the stock was trading at $23.50 at the time of the sale.

Stark's move wasn't an isolated event. He was one of seven different insiders who decided to trim their holdings on June 16. Other notable sellers included CEO Mark Reisenauer, who sold 98,748 shares, and President and COO Paul Schwichtenberg, who sold 78,811 shares. EVP and General Counsel Sam Schlessinger also offloaded 68,285 shares. Smaller sales were made by Heather Mason, who sold 42,081 shares, Emany Sravan Kumar, who sold 7,168 shares, and William Mckee, who matched Stark's move with a sale of 5,415 shares. None of these transactions were listed as being part of a pre-planned 10b5-1 trading schedule.

Assertio Holdings stock has been on a significant climb recently. On Tuesday, the stock was priced at $23.50, which is exactly at its 52-week high. This price is much higher than its 52-week low of $8.61 and sits comfortably above its 50-day moving average of $21.99. Investors often watch these moving averages to see if a stock has momentum; currently, Assertio is trading nearly 58% above its 200-day moving average of $14.90.

Financial Performance and Outlook

Assertio Holdings recently reported revenue of $102.16 million, though that represented a slight dip of 0.6% compared to the previous period. The company isn't currently profitable, posting an earnings per share (EPS) loss of $5.55. Because it isn't making money, the company doesn't have a traditional P/E ratio, though its forward P/E ratio—which estimates future earnings—sits at about 9.1. Its net margin is currently at -34.9%, and its return on equity is -38.8%.

Analysts Set New Price Targets

Even with the heavy insider selling, some analysts remain optimistic about where the stock is headed. The average price target among the three analysts covering the company is $24.43, suggesting there might still be a small amount of room for the stock to grow. The highest estimate on the street is $28.00, while the most conservative target is $21.80. Overall, the consensus recommendation for the stock is currently listed as a buy.

About Assertio Holdings

Assertio Holdings is a pharmaceutical company based in Lake Forest, Illinois. It focuses on providing specialized medicines, including treatments for rheumatoid arthritis, migraines, and seizures. Its product lineup includes well-known brands like Indocin and Cambia. The company has gone through significant changes in recent years, including a name change in 2020 as it shifted its focus within the drug manufacturing industry.

Looking ahead, investors will likely keep a close eye on the company's next earnings report to see if it can turn its revenue into profit. While insider selling can happen for many personal reasons, seeing seven different leaders sell on the same day while the stock is at a yearly high is a detail many market watchers will note. These filings reflect past transactions and don't necessarily show what these insiders plan to do with their remaining shares today.